These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28017434)

  • 1. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
    Sharma M; Seoud M; Kim JJ
    Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
    Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
    Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of human papillomavirus vaccination and screening in Spain.
    Diaz M; de Sanjose S; Ortendahl J; O'Shea M; Goldie SJ; Bosch FX; Kim JJ
    Eur J Cancer; 2010 Nov; 46(16):2973-85. PubMed ID: 20638840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage.
    Campos NG; Castle PE; Wright TC; Kim JJ
    Int J Cancer; 2015 Nov; 137(9):2208-19. PubMed ID: 25943074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru.
    Goldie SJ; Levin C; Mosqueira-Lovón NR; Ortendahl J; Kim J; O'Shea M; Diaz Sanchez M; Mendoza Araujo MA
    Rev Panam Salud Publica; 2012 Dec; 32(6):426-34. PubMed ID: 23370186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis.
    Georgalis L; de Sanjosé S; Esnaola M; Bosch FX; Diaz M
    Eur J Cancer Prev; 2016 Sep; 25(5):430-9. PubMed ID: 26375246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.
    Sharma M; Ortendahl J; van der Ham E; Sy S; Kim JJ
    BJOG; 2012 Jan; 119(2):166-76. PubMed ID: 21481160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of high-risk HPV DNA testing for cervical cancer screening in South Africa.
    Vijayaraghavan A; Efrusy M; Lindeque G; Dreyer G; Santas C
    Gynecol Oncol; 2009 Feb; 112(2):377-83. PubMed ID: 19081611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more.
    Goldie SJ; Kim JJ; Wright TC
    Obstet Gynecol; 2004 Apr; 103(4):619-31. PubMed ID: 15051550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
    Kim JJ; Wright TC; Goldie SJ
    J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.
    Campos NG; Tsu V; Jeronimo J; Njama-Meya D; Mvundura M; Kim JJ
    Health Policy Plan; 2017 Sep; 32(7):956-968. PubMed ID: 28369405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
    Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
    Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
    Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
    Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
    Demarteau N; Van Kriekinge G; Simon P
    Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of improving failures within a cervical cancer screening program: an example from Norway.
    Burger EA; Kim JJ
    Int J Cancer; 2014 Oct; 135(8):1931-9. PubMed ID: 24615416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of HPV DNA test as primary screening method for cervical cancer: A health policy discussion in Greece.
    Skroumpelos A; Agorastos T; Constantinidis T; Chatzistamatiou K; Kyriopoulos J
    PLoS One; 2019; 14(12):e0226335. PubMed ID: 31830114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.